Baudax Bio to Present at the Oppenheimer 32nd Annual Healthcare Conference
Baudax Bio, a pharmaceutical company focused on acute care products, announced that CEO Gerri Henwood will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 2:40 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Baudax Bio, a pharmaceutical company focused on acute care products, announced that CEO Gerri Henwood will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 2:40 p.m. ET. A live webcast of the presentation will be available on the company's investors page, and a replay will be accessible for 30 days post-event.
Baudax Bio is known for ANJESO, the first 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain, alongside a pipeline of innovative pharmaceutical products.
Details
News Market Reaction – BXRX
The recorded move for BXRX in the trading session of this news was -3.23%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 2:40 p.m. Eastern Time.
A live webcast of the presentation will be available on the “Events” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. A replay will be available on the Baudax Bio website for a period of 30 days following the event.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.
CONTACT:
Investor Relations Contact:
Argot Partners
Sam Martin / Kaela Ilami
(212) 600-1902
baudaxbio@argotpartners.com
Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.